Review: NSAIDS and COX-2 inhibitors may prevent colorectal cancer but increase gastrointestinal and cardiovascular harm

July 2007
ACP Journal Club;Jul/Aug2007, Vol. 147 Issue 1, p16
Academic Journal
The article cites a study, conducted by A. Rostom and colleagues, which focuses on the effectiveness of nonsteroidal antiinflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors in primary prevention of colorectal cancer. The researchers employed English language studies to evaluate the efficacy of NSAIDs and systematic reviews to assess the harms of these agents. They found that both NSAlDs and COX-2 inhibitors increase risk for cardiovascular harm.


Related Articles

  • Angiostatic Properties of Sulindac and Celecoxib in the Experimentally Induced Inflammatory Colorectal Cancer. Vaish, Vivek; Piplani, Honit; Rana, Chandan; Sanyal, Sankar // Cell Biochemistry & Biophysics;Jun2013, Vol. 66 Issue 2, p205 

    Initiation of various cancers has been observed to be regulated via a prolonged inflammatory state in the tissues. However, molecular role of such a localized inflammation is not clear in the advanced stages of colorectal cancer. In this study, we have elaborated the role of various pro- and...

  • Colorectal Cancer: A Summary of the Evidence for Screening and Prevention. WILKINS, THAD; REYNOLDS, PETER L. // American Family Physician;12/15/2008, Vol. 78 Issue 12, p1385 

    Colorectal cancer causes significant morbidity and mortality in the United States. The incidence of colorectal cancer can be reduced with increasing efforts directed at mass screening of average-risk adults 50 years and older. Currently, fecal occult blood test and flexible sigmoidoscopy have...

  • Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells. Strillacci, A.; Griffoni, C.; Lazzarini, G.; Valerii, M. C.; Di Molfetta, S.; Rizzello, F.; Campieri, M.; Moyer, M. P.; Tomasi, V.; Spisni, E. // British Journal of Cancer;9/28/2010, Vol. 103 Issue 7, p975 

    Background:Cyclooxygenase-2 (COX-2) overexpression is strongly associated with colorectal tumourigenesis. It has been demonstrated that the chronic use of non-steroidal anti-inflammatory drugs (COX inhibitors) partially protects patients from colorectal cancer (CRC) development and progression...

  • COX-2 Inhibition in Esophagitis, Barrett's Esophagus and Esophageal Cancer. Piazuelo, E.; Jimenez, P.; Lanas, A. // Current Pharmaceutical Design;Oct2003, Vol. 9 Issue 27, p2267 

    There is extensive evidence that cyclooxygenase-2 (COX-2) plays a significant role in the process of carcinogenesis in different tumors. Although most of these evidences derive from studies in colorectal cancer, data obtained from recent studies strongly suggest that COX-2 might play an...

  • Chemoprevention in Sporadic Colorectal Cancer: The Role of Salycilates, Nsaids and Coxibs. Manzano, A; PĂ©rez-Segura, P. // Journal of Cancer Science & Therapy;2012 Supplement, Vol. 4, p1 

    Sporadic colorectal cancer (CRC) represents 75% of the total of the CRC cases diagnosed and is the second leading cause of cancer death with a a 5-year survival rate of 62%. The development of colorectal cancer is a complex process involving multiple molecular pathways, since the formation of...

  • NSAIDs and colorectal cancer prevention. Iwama, Takeo // Journal of Gastroenterology;2009 Supplement 19, Vol. 44, p72 

    This article discusses the merits and limits of nonsteroidal antiinflammatory drugs (NSAIDs), including cyclooxygenase (COX)-2 inhibitors, for colorectal cancer prevention. The suppressive effect of NSAIDs on colorectal tumors has been recognized since as early as 1981. The chemopreventive...

  • ANTI-INFLAMMATORY OLIVE.  // American Herb Association Quarterly Newsletter;Autumn2007, Vol. 22 Issue 4, p13 

    The article investigates the potential therapeutic benefits of virgin olive oil (olea europaea) by researchers from University of Pennsylvania in Philadelphia, Pennsylvania. It is stated that olive oil contains a non-stereoidal compound that decreases several inflammatory reactions in the body,...

  • COX-2s confer QOL benefit in clinical practice in Latin America. Everitt, Laura // PharmacoEconomics & Outcomes News;7/31/2004, Issue 458, p3 

    Discusses research being done on the effectiveness of cyclo-oxygenase-2 (COX-2) inhibitors etoricoxib and rofecoxib in treating patients with chronic low back pain or osteoarthritis in Latin American countries, presented at the Annual European Congress of Rheumatology in Berlin, Germany in June...

  • Review: Selective COX-2 inhibitors increase vascular events more than placebo and naproxen, but not more than other NSAIDs.  // ACP Journal Club;Nov/Dec2006, Vol. 145 Issue 3, p66 

    The article presents information on a medical study that finds effects of selective cyclooxygenase-2 (COX-2) inhibitors on vascular events. Randomized controlled trials of four weeks in duration that compared a selective COX-2 inhibitor with placebo or a traditional non-steroidal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics